---
document_datetime: 2025-12-04 09:38:24
document_pages: 28
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/paxlovid-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: paxlovid-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 16.8421482
conversion_datetime: 2025-12-19 23:28:50.706686
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Paxlovid

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                               |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------|
| II/0061/G            | This was an application for a group of variations. A grouped application comprised of a Type II Variation and a Type IB Variation, as follows: Type II (C.I.6.a): Extension of indication to include | 16/10/2025                          | 26/11/2025                                  | SmPC, Labelling and PL           | Please refer to Scientific Discussion 'Paxlovid-H-C- 005973/II/0061/G |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| treatment of coronavirus in paediatric patients 6 weighing at least 20 kg final analysis of Cohorts C4671026; this is a Phase Pharmacokinetics, and Center, Single-Arm Study Administered PF 07321332 in Nonhospitalised Symptomatic Participants With COVID-19 Progression to Severe Disease. sections 4.1, 4.2, 4.8, 5.1, are updated. The Package accordance. A revised RMP approved. In addition, the holder (MAH) took the opportunity minor changes to the PI, with the latest QRD template the application, the MAH extension of the market Type IB (B.II.e.5.a.2): film-coated tablets (5 nirmatrelvir ritonavir tablets) specific years and older weighing and moderate renal impaired (EU/1/22/1625/003); the Labelling are updated accordingly. The group of variations Summary of Product Characteristics, Package Leaflet and Annex   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0059/G | This was an application for a group of variations. A grouped application consisting of: C.I.4: Update of section 4.5 of the SmPC in order to add drug-drug interaction information with albendazole based on the post-marketing data and literature and to update information on drug-drug interactions with methadone and ethinyl estradiol based on the literature; the Package Leaflet is updated accordingly. C.I.4: Update of section 4.5 of the SmPC in order to update information on drug-drug interactions with calcium channel antagonists based on the cumulative safety data and literature. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 10/07/2025 | 21/11/2025 | SmPC and PL | SmPC new text Section 4.5 - Table 2: Interaction with other medicinal products and other forms of interaction: - Analgesics - Methadone: Increased methadone dose may be necessary when coadministered with ritonavir dosed as a pharmacokinetic enhancer due to induction of glucuronidation. Monitor methadone-maintained patients closely for evidence of withdrawal effects. Dose adjustment should be considered based on the patient's clinical response to methadone therapy. - Antiparasitic agent- Albendazole: Significant decreases in plasma concentrations of albendazole and its active metabolite may occur due to induction by ritonavir, with a risk of decreased albendazole efficacy. Clinical monitoring of therapeutic response and possible adjustment of albendazole dosage during treatment with Paxlovid and following discontinuation is recommended. - Calcium channel antagonists - Amlodipine, Diltiazem, Felodipine, Nicardipine, Nifedipine, Verapamil: Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        | expected to increase the plasma concentrations of calcium channel antagonists. Consultation of a multidisciplinary group should be obtained to guide on the best way to handle the drug interaction by dose decrease or even temporary discontinuation of calcium channel antagonist when coadministered with Paxlovid. Moreover, if coadministered, patients should be carefully monitored for therapeutic and adverse effects during the coadministration. Refer to individual calcium channel antagonist SmPCs for more information. - Hormonal contraceptive: Due to reductions in ethinyl estradiol concentrations, barrier or other non hormonal methods of contraception should be considered with concomitant Paxlovid use and until one menstrual cycle after stopping Paxlovid. Ritonavir is likely to change the uterine bleeding profile and reduce the effectiveness of estradiol-containing contraceptives. For more information, please refer to the Summary of   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0057/G | This was an application for a group of variations. Grouped application consisting of: C.I.4: Update of sections 4.2, 4.4, 4.8 and 5.2 of the SmPC in order to provide a new dosing recommendation in patients with severe renal impairment based on final results from study C4671028; this is a Phase 1, Open-Label, Non- Randomized Study to Investigate the Safety and PK Following Multiple Oral Doses of PF-07321332 (Nirmatrelvir)/Ritonavir in Adult Participants With COVID-19 and Severe Renal Impairment Either on | 27/03/2025 | 02/05/2025 | SmPC, Labelling and PL | SmPC new text Submission of the final results from study C4671028 which evaluated the safety and pharmacokinetics following multiple oral doses of Paxlovid in adult participants with COVID-19 and severe renal impairment either on haemodialysis or not on haemodialysis. The available data supports the updated posology in patients with severe renal impairment (eGFR < 30 mL/min), including those requiring haemodialysis, of 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) in Day 1 and a maintenance dose of 150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) for Day 2                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | Hemodialysis or Not on Hemodialysis. The Package Leaflet and Labelling are updated accordingly. The updated RMP version 3.1 has been approved. In addition, the MAH took the opportunity to implement editorial changes to the product information. B.II.e.5.a.2: To introduce a new pack size for a 5- day regimen blister card of 11 tablets, specific to severe renal impairment. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             | to Day 5. This schedule allows to each more rapidly an effective concentration, and to maintain its level largely above the EC90 across the dosing interval. No new safety concerns are identified in this population. To ensure safe and effective use in patients with severe renal impairment, a new pack size of 11 film-coated tablets (6 nirmatrelvir tablets + 5 ritonavir tablets). For more information, please refer to the Summary of Product Characteristics.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0060 | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/03/2025 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0056 | Update of section 4.6 and 5.2 of the SmPC in order to update information on breastfeeding based on final results from study C4671039 listed as a category 3 study in the RMP (MEA/018.2); this is a Phase I, multiple dose, pharmacokinetic and safety study in healthy lactating adult women. The package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                 | 03/10/2024 | 02/05/2025 | SmPC and PL | SmPC new text Information regarding breastfeeding is updated in the SmPC (4.6 and 5.2). Nirmatrelvir and ritonavir are excreted in breast milk. Breast feeding should be discontinued during treatment and as a precautionary measure for 48 hours after completing Paxlovid. For more information, please refer to the Summary of Product Characteristics.                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| II/0051/G   | This was an application for a group of variations.                                                                                                                                                                                                           | 19/09/2024   | 02/05/2025   | SmPC        | New SmPC text                                                                                                                                                                                                                                                                                                                                         |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0052/G   | This was an application for a group of variations. Within a grouped variation which comprised of 2 Type II Variations, an update is done as follows: C.I.4: Update of sections 4.3 and 4.5 of the SmPC in order to include more detailed information for the | 12/09/2024   | 02/05/2025   | SmPC and PL | SmPC new text Section 4.3 ,4.5 of the SmPC are updated to include more information for the drug-drug interactions (DDIs) related to venetoclax, apixaban, saxagliptin and cariprazine and to remove the reference to the dabigatran SmPC in the dabigatran DDI clinical comments. The interaction information related to enzalutamide, lercanidipine, |

<div style=\"page-break-after: always\"></div>

|           | drug-drug interactions (DDIs) related to venetoclax, apixaban, saxagliptin and cariprazine and to remove the reference to the dabigatran SmPC in the dabigatran DDI clinical comments. In addition, the interaction information related to enzalutamide, lercanidipine, bosentan and efavirenz and other HMG Co-A reductase inhibitors is also updated. C.I.4: Update of section 5.2 of the SmPC in order to include additional information related to the rosuvastatin DDI, based on the final results from study C4671052; this is a phase 1, randomized, fixed sequence, multiple dose, open-label study to estimate the effect of nirmatrelvir/ritonavir on rosuvastatin pharmacokinetics in healthy adult participants. As a consequence, the SmPC is updated, and the Product leaflet is also updated accordingly. Moreover, the MAH took the opportunity to make some minor editorial changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to   |            |            | bosentan and efavirenz and other HMG Co-A reductase inhibitors is also updated. Also section 5.2 of the SmPC is being updated to include additional information related to the rosuvastatin DDI, based on the final results from study C4671052. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0058 | A.3 - Administrative change - Change in name of the AS or of an excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/08/2024 | 19/09/2024 | SmPC and PL                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| PSUSA/10984 /202312   | Periodic Safety Update EU Single assessment - nirmatrelvir / ritonavir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/07/2024   | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                         |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0055               | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 14/05/2024   | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                           |
| IAIN/0053             | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 13/03/2024   | 19/09/2024 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                           |
| PSUSA/10984 /202306   | Periodic Safety Update EU Single assessment - nirmatrelvir / ritonavir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 08/02/2024   | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                         |
| II/0049/G             | This was an application for a group of variations. Grouped application comprising two type II variations (C.I.4) as follows: - Update of section 4.4 and 4.8 of the SmPC in order to clarify that toxic epidermal necrolysis has been reported with Paxlovid and to add toxic epidermal necrolysis to the list of adverse drug reactions (ADRs) with frequency Rare based on the cumulative review of MAH safety database and literature. - Update of section 4.4 and 4.8 of the SmPC in order to clarify that Stevens-Johnson syndrome has been reported with Paxlovid and to add Stevens-Johnson syndrome to the list of adverse drug reactions (ADRs) with frequency Rare, based on the cumulative review of MAH safety database and literature. | 14/12/2023   | 19/09/2024 | SmPC and PL     | SmPC new text Sections 4.4 and 4.8 are updated to complement information regarding cutaneous adverse reactions. Thus, serious skin reactions (including toxic epidermal necrolysis and Stevens-Johnson syndrome) are included as they have been reported with Paxlovid use. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10984 /202212 | Periodic Safety Update EU Single assessment - nirmatrelvir / ritonavir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/09/2023 | 20/11/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10984/202212.                                                                                                                                                                                                                                                               |
| II/0040/G           | This was an application for a group of variations. Grouped application comprising two type II variations as follows: - Update of section 4.3 of the SmPC in order to add more information for medicinal products such as finerenone ,naloxegol, lumacaftor/ivacaftor, etc, under medicinal products that are that are highly dependent on CYP3A for clearance or potent CYP3A inducer which ,therefore, could lead to serious and/or life-threatening reactions if co-administered with Paxlovid. - Update of section 4.5 of the SmPC in order to add drug-drug interaction information regarding co- administration of Paxlovid with different medicinal products that are metabolized by CYP3A4 or CYP2D6, transported by P-gp, or induce CYP3A4. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 14/09/2023 | 26/10/2023 | SmPC and PL | SmPC new text Sections 4.3 and 4.5 of the SmPC are updated to introduce additional information regarding drug-drug interaction with medicines that are metabolized by CYP3A4 or CYP2D6, transported by P-gp, or induce CYP3A4.Moreover, opportunity is taken to further adjust the drug- drug interaction recommendations. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|           | data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                       |            |            |             |                                                                                                                                                                                                                                                                                                               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0048   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                               | 10/10/2023 | 19/09/2024 | SmPC and PL |                                                                                                                                                                                                                                                                                                               |
| IB/0047   | B.I.d.z - Stability of AS - Other variation                                                                                                                                                                                                                                  | 30/08/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                               |
| IA/0045   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                   | 27/07/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                               |
| IA/0046/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 24/07/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                               |
| II/0043/G | This was an application for a group of variations. Grouped application comprising two type II variations as follows: -Update of section 5.1 of the SmPC in order to include new virology updates. - Update of sections 4.5 and 5.2 of the SmPC in                            | 20/07/2023 | 26/10/2023 | SmPC        | SmPC new text Within this variation new information about in vitro drug- drug interaction is included in the SmPC. This is: • CYB2B6 is added to the list of enzymes that may be induced by PAXLOVID and to the list of enzymes that nirmatrelvir does not inhibit. • MATE1 and OCT1 are added to the list of |

<div style=\"page-break-after: always\"></div>

|           | order to update interaction information related to CYP2B6, MATE1 and OCT1. The RMP version 3.0 has also been submitted and updated. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                 |            |            |      | transporters for which nirmatrelvir has low potential to inhibit. The MAH has also updated the antiviral activity against SARS-CoV-2 variants. Overall, no decrease of antiviral activity of Paxlovid is expected against the currently circulating SARS-CoV-2 XBB.1.5 variant. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0042   | Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy, safety and pharmacokinetic information, based on updated results from studies C4671005 (EPIC-HR), C4671002 (EPIC-SR) and C4671006 (EPIC-PEP) as well as a supplemental report to Pop PK analysis PMAR-EQDD-C467a-DP4- 1323, following the reanalysis of data after the removal of data related to four sites from the Paxlovid data analysis. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 20/07/2023 | 26/10/2023 | SmPC | Please refer to Scientific Discussion 'Product Name-H-C- Product Number-II-42' For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                    |
| IA/0044/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                                                                                                                                                                           | 28/06/2023 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0032 | Update of section 4.4 of the SmPC in order to include a warning on the risk of hypertension and to recommend a monitoring of blood pressure, and update of section 4.8 to add 'hypertension' to the list of adverse drug reactions (ADRs) with frequency 'uncommon', based on review of aggregate post- marketing data. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 12/05/2023 | 23/06/2023 | SmPC and PL | Hypertension was detected as a signal in post-marketing experience. Post marketing analysis revealed at a least possible causal relationship to Paxlovid, in terms of temporal association and lack of confounding factors. A warning was consequently added in section 4.4 of the SmPC to further alert prescribers on the risk of hypertension and to recommend the monitoring of blood pressure during Paxlovid therapy (self-monitoring for outpatients) in order to initiate or re-assess antihypertensive treatment if necessary. For more information, please refer to the Summary of Product Characteristics. |
| II/0037 | Submission of the updated population modeling analysis report (PMAR-EQDD-C467a-Other-1463): population pharmacokinetics of nirmatrelvir/ritonavir after oral administration in adults with/without COVID-19 - a pooled analysis of phase 1/2/3 data. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                    | 12/05/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0036 | Update of sections 4.4, and 4.5 of the SmPC in order to include a warning related to Immunosuppressants                                                                                                                                                                                                                                                                                                                                                                               | 30/03/2023 | 26/04/2023 | SmPC        | The Product Information has been updated to include a warning related to immunosuppressants, and to update the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | and to update the information regarding co- administration with Immunosuppressants following the assessment of procedure II/0010/G based on the cumulative review of the spontaneous reports of over-exposure/over-toxicity of immunosuppressants and literature review. In addition, the MAH took this opportunity to introduce minor editorial changes to the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                 |            |     | information regarding co-administration with immunosuppressants to enhance the physicians' attention on the complexity of the management in the target population. Such amendment follows the assessment of procedure II/0010/G based on the cumulative review of the spontaneous reports of over-exposure/over-toxicity of immunosuppressants and literature review. For more information, please refer to the Summary of Product Characteristics and Package Leaflet   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0041/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 17/04/2023 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0038   | B.II.d.2.z - Change in test procedure for the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 07/03/2023 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| II/0019/G   | This was an application for a group of variations.                                               | 26/01/2023   | 24/02/2023   | Annex II    | The SmPC section 5.1 has been updated by deleting the text below:                                                  |
|-------------|--------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------------------------------------------------------------------------------------------------------|
| II/0026/G   | This was an application for a group of variations. - Update of section 4.6 to update information | 26/01/2023   | 15/02/2023   | SmPC and PL | This grouped variation application concerns the several updates of the SmPC generated from different data sources. |

<div style=\"page-break-after: always\"></div>

related to the nonclinical data on developmental toxicity without change the recommendation based on cases reported on on-going clinical trials C4671002, C4671005 and C4671006, or reported during post-marketing, and the pre- and post-natal development study report 21GR149.

-

Update of section 5.1 of the SmPC in order to include final clinical efficacy and safety data based

on the pivotal C4671005 study. Section 5.1 of the

SmPC is also updated to include the antiviral activity of nirmatrelvir, against the sub-variants

B.1.1.529/BA.1, BA.2, BA.2.12.1, BA.4, and BA.5, antiretroviral resistance information based on in vitro

assays and viral load rebound and treatment- emergent mutations observed in clinical practice.

-

Update of section 5.2 of the SmPC in order to update pharmacokinetic data on the effect of food

on oral absorption following the submission of the results from studies C4671012, C4671013, C467104,

C4671015 and C4671019.  The first four studies are

DDI studies conducted in healthy volunteers, with dabigatran, midazolam, carbamazepine and

itraconazole, respectively. C4671019 was a phase 1, open-label, randomised, single dose, 2-sequence, 2-

period crossover study to evaluate the effect of high- fat meal on the relative bioavailability of nirmatrelvir

boosted with ritonavir following after single oral dose administration in healthy adult participants.

The MAH has taken the opportunity to include editorial changes are included in sections 4.2, 4.5,

4.8 and 6.1 of the SmPC and the Package Leaflet.

In relation to pregnancy, data on animal studies showed there were no nirmatrelvir-related severe manifestations of developmental toxicity at the highest dose tested in rats and rabbits. There were no nirmatrelvir-related adverse effects on pre- and post-natal development up to the highest dose tested in rats. Clinical data included identified 7 cases of maternal exposure during pregnancy in the ongoing clinical trials: in 4 of the 7 cases, female study participants received placebo, in 3 of the 7 cases the pregnancies occurred in female partners of male study participants receiving nirmatrelvir/ritonavir. There were no associated adverse events in any of the 3 cases. In all 3 cases the outcome of the pregnancies was unknown at the time of reporting. At the time of reporting there were 2 post-marketing cases of pregnancy. In 1 of the postmarketing cases, a female took nirmatrelvir/ritonavir at 27 weeks gestation and adverse events of Ageusia and Anosmia were co-reported. In the second post-marketing case no adverse were reported. Based on review of available pregnancy data, no update to the recommendation is considered necessary, although based on this review section 4.6 of the SmPC is slightly updated. In relation to pharmacodynamic properties, in vitro cell culture data showed nirmatrelvir antiviral activity against Omicron subvariants BA.1, BA.2, BA.4 and BA.5 with EC50 fold changes compared to wildtype of ≤1. Also, a list of SARS-CoV-2 Mpro amino acid substitutions selected by nirmatrelvir in cell culture (with EC50 fold change &gt;5) have been included in the SmPC, although the clinical significance of these mutations needs to be further understood. Lastly, in relation to antiviral rebound, the SmPC was updated to indicate that post-treatment viral

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | nasal RNA rebounds were observed on Day 10 and/or Day 14 in a subset of Paxlovid and placebo recipients in EPIC- HR, irrespective of COVID-19 symptoms. The incidence of viral rebound in EPIC-HR occurred in both the Paxlovid treated participants and the untreated (placebo) participants, but at higher incidence in the Paxlovid arm (6.96% vs. 4.08%). So far, viral rebounds and symptoms recurrences of COVID-19 are not associated with more severe disease or emergence of resistance. In relation to clinical efficacy, the first key secondary efficacy results from the pivotal trial C4671005 were updated. The observed event rate of COVID-19-related hospitalisation or death from any cause through Day 28 in the mITT1 analysis set who received treatment within 5 days of symptom onset was 66 of 1046 (6.310%) participants in the placebo group, and 9 of 1039 (0.866%) participants in the Paxlovid group, showing an 86.3% (72.6% to 93.1%) relative risk reduction in observed endpoint events. This change in the primary endpoint relative risk reduction from 87.8% as reported in the C4671005 primary completion date CSR was due to the reporting of a late event of a hospitalisation. This was a newly reported primary event (COVID-19-related hospitalization at Day 2) for a participant in the Paxlovid treatment group.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0028/G | This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters                                                                                                                                                                                                                                                  | 02/02/2023 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | new specification parameter to the specification with its corresponding test method B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.b.3.a - Change in the manufacturing process of   |            |            |                     |                                                                                                                  |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|------------------------------------------------------------------------------------------------------------------|
| IB/0033 | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 24/01/2023 | 15/02/2023 | SmPC, Labelling and | To update the product information to extend the shelf life of the finished product from '18 months' to '2 years' |

<div style=\"page-break-after: always\"></div>

|                     | variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            | PL          | (section 6.3 of the SmPC) and to change the storage conditions from 'Do not store above 25 °C. Do not refrigerate or freeze.' to 'This medicinal product does not require any special storage conditions.'                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10984 /202206 | Periodic Safety Update EU Single assessment - nirmatrelvir / ritonavir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 12/01/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0035             | B.I.d.z - Stability of AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/01/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0010/G           | This was an application for a group of variations. Update of sections 4.4 and 4.8 of the SmPC to add hypersensitivity to the list of adverse drug reactions with frequency uncommon and anaphylaxis with frequency rare, including a warning on hypersensitivity reactions, based on a cumulative search of the MAH safety database. The Package Leaflet is updated accordingly. Update of section 4.5 of the SmPC in order to add drug-drug interaction information with dabigatran and rivaroxaban (P-gp substrate) based on the clinical study results from study C4671012, a pharmacokinetic study to estimate the effect of Paxlovid on the pharmacokinetics of dabigatran; the Package Leaflet is updated accordingly. Update of section 4.5 of the SmPC in order to update the drug-drug interaction information of midazolam based on the clinical study results from study C4671013, a pharmacokinetic study to estimate the effect of Paxlovid on the pharmacokinetics of midazolam. | 15/12/2022 | 22/12/2022 | SmPC and PL | Based on a safety review on the use of Paxlovid, the following changes are included in the product information: • Anaphylaxis and other hypersensitivity reactions have been reported with Paxlovid. Cases of Toxic Epidermal Necrolysis and Stevens-Johnson syndrome have been reported with ritonavir, a component of Paxlovid. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue Paxlovid and initiate appropriate medications and/or supportive care. • Concomitant administration of Paxlovid is expected to increase dabigatran concentrations resulting in increased risk of bleeding. Reduce dose of dabigatran or avoid concomitant use. Refer to the dabigatran Summary of the product charactestics (SmPC) for further information. Rivaroxaban is not recommended as it's metabolisation may be impacted by the CYP3A4 inhibitory effect of Paxlovid but also its P-gp inhibitory effect. • The new information obtained from a drug-drug interaction study conducted with Paxlovid and midazolam does not downgrade the magnitude of interaction pertaining to inhibition of CYP3A4, although the |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| The MAH has taken the opportunity to update sections 4.3, 4.4 and 4.5 of the SmPC in relation to the drug-drug interaction profile for Paxlovid: pethidine has been removed as a contraindicated medication; tadalafil, silodosin, eplenerone, ivabradine, voclosporin, eletriptan, tolvaptan, and apalutamide have been added as contraindicated medications; and sirolimus and lercanidipine have been added to list of interactions in section 4.5 of the SmPC. Also drugs propoxyphene, bepridil, encainide, astemizole, norbuprenophine, vorapaxar and desipramine have been removed from the SmPC as they are no longer marketed into the EU. Lastly, the SmPC was also updated to incite for a multidisciplinary approach for best handling the potential co-medications. The MAH is taking the opportunity to include editorial updates in sections 4.3, 4.4, 4.5, 5.1 and 5.2 of the SmPC. The package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     | • Lercanidipine should be avoided in co- administration with Paxlovid. The differential recommendation as compared to other calcium channel inhibitors as lercanidipine is particularly sensitive to CYP3A4 inhibition. • Depending on the type of drug-drug interaction, a multidisciplinary approach is recommended. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0034/G | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                     | 16/12/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0029/G | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.z - Change in manufacture of the Finished Product - Other variation B.II.d.2.z - Change in test procedure for the finished | 01/12/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|             | - Change in the specification parameters limits of the finished product - Other variation - Changes in the composition (excipients) the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                                  | B.II.d.1.z and/or B.II.a.3.z of   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| R/0023      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/11/2022 | 28/11/2022 |                                  |                                   |
| IAIN/0031/G | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code A.3 - Administrative change - Change in name of the                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/11/2022 | 22/12/2022 | SmPC, Annex II, Labelling and PL | AS or of an excipient             |
| II/0017     | Submission of the final report from study in vivo efficacy of Pf-07321332 as a single agent or in combination with ritonavir in Balb/C Mouse-Adapted SARS-CoV-2 Model. The objective of this study was to evaluate whether Ritonavir has in vivo antiviral activity against SARS-CoV-2 and whether combination of Ritonavir with PF-07321332 increased the exposure of PF-07321332 in the mouse model and further decreased viral lung replication. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 10/11/2022 | n/a        |                                  |                                   |
| II/0016/G   | This was an application for a group of variations. Update of section 4.8 of the SmPC in order to include the adverse drug reactions: nausea with frequency                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/10/2022 | 20/10/2022 | SmPC and PL                      |                                   |

<div style=\"page-break-after: always\"></div>

|         | common, abdominal pain with frequency uncommon and malaise with frequency rare; based on the global safety database of the MAH and literature review. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |      |                                                                                                        |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------|
| II/0007 | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                             | 29/09/2022 | n/a        |      |                                                                                                        |
| IB/0022 | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                   | 19/09/2022 | 29/09/2022 | SmPC | To change the summary of product characteristics, section 6.3 Shelf life from '1 year' to '18 months'. |
| IB/0020 | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                                                                                                                                                                                                                                 | 15/09/2022 | n/a        |      |                                                                                                        |
| II/0008 | Submission of the final report from study PMAR- EQDD-C467a-DP4-1323, listed as a legally binding measure. This is the updated population                                                                                                                                                                                                                                                                                                                                                                                                                  | 15/09/2022 | n/a        |      |                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | pharmacokinetics module results including PK data from the patients enrolled in the EPIC-HR study of Paxlovid. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                  |            |            |          |                                             |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------------------------------|
| IB/0025 | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                    | 09/09/2022 | n/a        |          |                                             |
| IB/0027 | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                       | 08/09/2022 | n/a        |          |                                             |
| II/0015 | Submission of an exploratory lipid analysis conducted retrospectively using the left-over safety and PK samples from the multiple ascending dose (PART-2) of study C4671001 (phase I randomised controlled trial) submitted as part of the initial marketing authorisation. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 01/09/2022 | n/a        |          |                                             |
| IB/0018 | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                | 30/08/2022 | 29/09/2022 | Annex II | To delete specific obligtion 4 in Annex II. |
| IA/0024 | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold                                                                                                                                                                                                                                                                                   | 12/08/2022 | n/a        |          |                                             |

<div style=\"page-break-after: always\"></div>

|           | compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------|
| IA/0021   | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/07/2022 | n/a        |             |               |
| II/0012/G | This was an application for a group of variations. C.I.13 (type II): Submission of the whole body autoradiographic study report in rats with PF- 07321332 (alone). C.I.13 (type II): Update of section 5.3 of the SmPC to indicate that no adverse effects were observed during the pre-and postnatal development study based on final study report for the pre- and postnatal development (21GR149). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission the competent authority | 07/07/2022 | 29/09/2022 | SmPC        | of studies to |
| II/0009   | Update of sections 4.3 and 4.5 of the SmPC in order to remove piroxicam as a contraindicated medicinal product and to indicate that piroxicam exposure may be decreased due to interaction with Paxlovid, based on scientific literature. The package leaflet is updated accordingly.                                                                                                                                                                                                                                                                                                                                                                                               | 23/06/2022 | 01/07/2022 | SmPC and PL |               |

<div style=\"page-break-after: always\"></div>

|           | - Change(s) in the SPC, Labelling or PL due to quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                                                                             |            |     | C.I.4 new data   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------|
| IB/0006   | B.II.e.z - Change in container closure system of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                        | 14/06/2022 | n/a |                  |
| IA/0014/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                     | 18/05/2022 | n/a |                  |
| IAIN/0013 | B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                                                                                                                                                                                                                          | 18/05/2022 | n/a |                  |
| IB/0005/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.z - Change in control of the AS - Other | 11/05/2022 | n/a |                  |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0003/G | This was an application for a group of variations. B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP                                                         | 22/04/2022 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0001/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 22/04/2022   | 01/07/2022   | PL   | The Annex II has been updated to include the name and                                                                                                                           |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation |              |              |      | address of the new manufacturer responsible for batch release as follows: Pfizer Ireland Pharmaceuticals Little Connell Newbridge Ireland The PL have been updated accordingly. |

<div style=\"page-break-after: always\"></div>

|         | arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site   |            |     |        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------|
| II/0002 | B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of and/or the FP                                    | 17/03/2022 | n/a | the AS |